STEAP2 and neoplasm: This is challenging to evaluate in some in vivo studies owing to the lack of viable tumor tissue at the end of study, but in the CTG-2440 and LuCaP 73 models dosed at the 5 × 105 cell sub-efficacious levels (Figure 6D), we observed consistent STEAP2 IHC scoring before and after CAR-T dosing.